Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

Christel C.L.M. Boons; Vashti N.M.F. Tromp; Nienke J.M. Neppelenbroek; Lonneke Timmers; Natasja M. van Schoor; Eleonora L. Swart; N. Harry Hendrikse; Jeroen J.W.M. Janssen; Jacqueline G. Hugtenburg

doi:https://doi.org/10.1080/0284186X.2019.1585944

Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

Christel C.L.M. Boons, Vashti N.M.F. Tromp, Nienke J.M. Neppelenbroek, Lonneke Timmers, Natasja M. van Schoor, Eleonora L. Swart, N. Harry Hendrikse, Jeroen J.W.M. Janssen, Jacqueline G. Hugtenburg

Research output: Contribution to journal › Letter › Academic › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	891-896
Number of pages	6
Journal	Acta Oncologica
Volume	58
Issue number	6
DOIs	https://doi.org/10.1080/0284186X.2019.1585944 https://doi.org/10.1080/0284186x.2019.1585944
Publication status	Published - 3 Jun 2019

Access to Document

Cite this

Boons, C. C. L. M., Tromp, V. N. M. F., Neppelenbroek, N. J. M., Timmers, L., van Schoor, N. M., Swart, E. L., Hendrikse, N. H., Janssen, J. J. W. M., & Hugtenburg, J. G. (2019). Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients. Acta Oncologica, 58(6), 891-896. https://doi.org/10.1080/0284186X.2019.1585944, https://doi.org/10.1080/0284186x.2019.1585944

@article{470dfb08e7354b278094927d18260035,

title = "Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients",

author = "Boons, {Christel C.L.M.} and Tromp, {Vashti N.M.F.} and Neppelenbroek, {Nienke J.M.} and Lonneke Timmers and {van Schoor}, {Natasja M.} and Swart, {Eleonora L.} and Hendrikse, {N. Harry} and Janssen, {Jeroen J.W.M.} and Hugtenburg, {Jacqueline G.}",

note = "Funding Information: The authors are responsible for the content of the article. J.J.W.M. Janssen is an advisory board member for Abbvie, Incyte, Jazz Pharmaceuticals, and Pfizer, and has received research support funding from Novartis and Bristol Myers Squibb and speaker{\textquoteright}s fees from Incyte and Pfizer. The other authors report no conflicts of interest. Funding Information: The data collection for this work was supported by an unrestricted grant by Novartis [CAMN107ENL04T]. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = jun,

day = "3",

doi = "https://doi.org/10.1080/0284186X.2019.1585944",

language = "English",

volume = "58",

pages = "891--896",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

AU - Boons, Christel C.L.M.

AU - Tromp, Vashti N.M.F.

AU - Neppelenbroek, Nienke J.M.

AU - Timmers, Lonneke

AU - van Schoor, Natasja M.

AU - Swart, Eleonora L.

AU - Hendrikse, N. Harry

AU - Janssen, Jeroen J.W.M.

AU - Hugtenburg, Jacqueline G.

N1 - Funding Information: The authors are responsible for the content of the article. J.J.W.M. Janssen is an advisory board member for Abbvie, Incyte, Jazz Pharmaceuticals, and Pfizer, and has received research support funding from Novartis and Bristol Myers Squibb and speaker’s fees from Incyte and Pfizer. The other authors report no conflicts of interest. Funding Information: The data collection for this work was supported by an unrestricted grant by Novartis [CAMN107ENL04T]. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/6/3

Y1 - 2019/6/3

UR - http://www.scopus.com/inward/record.url?scp=85063365588&partnerID=8YFLogxK

U2 - https://doi.org/10.1080/0284186X.2019.1585944

DO - https://doi.org/10.1080/0284186X.2019.1585944

M3 - Letter

C2 - 30905234

SN - 0284-186X

VL - 58

SP - 891

EP - 896

JO - Acta Oncologica

JF - Acta Oncologica

IS - 6

ER -

Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients

Access to Document

Other files and links

Cite this